Description

Revvity, Inc., originally established in 1937 and headquartered in Waltham, Massachusetts, operated as PerkinElmer, Inc. until its rebranding in April 2023. This global company is a key provider of diverse products, services, and specialized solutions across the diagnostics, life sciences, and applied services sectors. Its operations are divided into two primary segments: 1. Discovery & Analytical Solutions: This segment furnishes a comprehensive array of tools, including instruments, reagents, informatics platforms, software, subscription services, and advanced detection and imaging technologies. These offerings are designed to empower scientists in accelerating research discoveries within the life sciences. Beyond direct product sales, this segment also delivers contract research and laboratory services. Furthermore, it offers analytical solutions and services to assess environmental health, specifically concerning air, water, and soil quality. It also caters to the agricultural sector with solutions for farmers and food producers and provides specialized analytical instrumentation for diverse industrial applications such as the chemical, semiconductor, electronics, energy, lubricant, petrochemical, and polymer industries. 2. Diagnostics: This segment focuses on providing instruments, reagents, assay platforms, and software products critical for the early identification of genetic disorders, particularly during pregnancy and early childhood, as well as for infectious disease screening. Its diagnostic tools are employed in the screening and testing for a range of genetic abnormalities and conditions, including Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic disorders. This segment is also involved in developing advanced technologies that facilitate genomic workflows, utilizing techniques like protein-coupled receptor analysis and next-generation DNA sequencing, with applications spanning oncology, immunodiagnostics, and drug discovery. Revvity serves a broad clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health organizations, private healthcare providers, medical professionals, and governmental bodies.